Patients with diabetes and multi-vessel heart disease did better with cardiac bypass surgery than patients treating using drug-eluting stents, according to a 5-year study comparing the therapies.
The Freedom trial found that the CABG arm of the 1,900-patient study had fewer adverse events and lower mortality rates than the percutaneous coronary intervention cohort.